The InterView Fusion and InterView XP reportedly improve image quality for single-photon emission computed tomography (SPECT) and offer imaging tools specifically geared to common nuclear medicine studies ranging from bone imaging to cardiac assessment and lung imaging.
Specifically tailored to workflows for nuclear medicine and molecular imaging, the InterView™ Fusion (Mediso) and InterView XP (Mediso) multimodality (PET/SPECT/MRI/CT) image processing and reporting software have garnered 510(k) clearance from the Food and Drug Administration (FDA).
In addition to bolstering image quality for single-photon emission computed tomography (SPECT) with iterative reconstruction, the InterView software offers specialized tools for a variety of common nuclear medicine studies including cardiac, bone, thyroid, liver, and lung imaging, according to Mediso.
The company said the InterView software also features a variety of modules that facilitate automated lesion detection and segmentation as well as image denoising.
In addition to bolstering image quality for single-photon emission computed tomography (SPECT) with iterative reconstruction, the InterView software offers specialized tools for a variety of common nuclear medicine studies including bone imaging. (Images courtesy of Mediso.)
Mediso added that the vendor independent software can be utilized on stand-alone workstations or be incorporated seamlessly into physical or virtual servers of hospital information systems.
“The InterView software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research application, and they demonstrate our continuous commitment to the molecular imaging market,” noted Istvan Bagamery, the founder and CEO of Mediso.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
August 5th 2025An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
August 5th 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.